Pediatric Drugs: the Worldwide Market, 3rd Edition

Table of Contents

Chapter One: Executive Summary

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting the World Prescription Pediatric Market
• Leading Competitors

Chapter Two: Introduction

• The Evolution of Child Healthcare
• History and Growth of the Pediatric Drug Market
  • Absorption
  • Distribution
  • Biotransformation
  • Excretion
• Demographics
• Treatment Guidelines for Pediatric Populations

Chapter Three: Prescription Allergy and Respiratory Drugs

• Overview
• Description of Conditions and Diseases
  • Seasonal Conditions
  • Long Term Conditions
  • Prevalence and Incidence
• Description of Products
  • Antihistamines and Combinations
  • Antiasthmatic Agents
  • Bronchodilators
  • Corticosteroids
  • Decongestants and Combinations
  • Expectorants, Antitussives, and Combinations
  • Lung Surfactants
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
  • Competitive Analysis

Chapter Four: Prescription Pediatric Anti-Infectives

• Overview
• Description of Conditions and Diseases
  • Respiratory Viral and Bacterial Conditions and Diseases
  • Upper Respiratory Tract Infections
  • Blood and Immune-Related Bacterial and Viral Infections
  • Childhood Diseases
  • Urinary Tract Infections (UTI)
  • Parasitic Infections
  • Miscellaneous Bacterial and Viral Infections
  • Prevalence and Incidence
• Description of Products
  • Antibiotics
  • Antifungals
  • Anti-Parasitics
  • Antivirals
  • Miscellaneous Anti-Infectives
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
• Competitive Analysis

Chapter Five: Prescription Pediatric Cancer Therapies

• Overview
• Description of Diseases
  • Leukemia
  • Lymphomas
  • Brain Tumors
  • Neuroblastoma
  • Osteogenic Sarcoma
  • Ewing' s Sarcoma
  • Wilms Tumor
  • Rhabdomyosarcoma
  • Retinoblastoma
• Incidence
• Description of Products
  • Alkylating Agents
  • Antimetabolites
  • Antineoplastic Antibiotics
  • Mitotic Inhibitors
  • Miscellaneous Cancer Therapies
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
• Competitive Analysis

Chapter Six: Prescription Pediatric Cardiovascular Drugs

• Overview
• Description of Conditions and Diseases
  • Congenital Heart Disease (CHD)
  • Congestive Heart Failure (CHF)
  • Hypertension
  • Hyperlipidemia/Hypercholesterolemia
  • Cardiomyopathy
• Prevalence and Incidence
  • Congenital Heart Disease
  • Congestive Heart Failure
  • Hypertension
  • Hyperlipidemia/Hypercholesterolemia
  • Cardiomyopathy
• Description of Products
  • Anticoagulants
  • Antidysrhythmics
  • Antihypertensives
  • Cardiac Glycosides
  • Miscellaneous Cardiovascular Drugs
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
  • Competitive Analysis

Chapter Seven: Prescription Pediatric Central Nervous System Drugs

• Overview
• Description of Conditions and Diseases
  • Epilepsy
  • Attention Deficit Hyperactivity Disorder
  • Childhood Depression
  • Mental Disorders
  • Pain
  • Anesthesia
  • Enuresis
  • Juvenile Rheumatoid Arthritis
• Prevalence and Incidence
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Childhood and Adolescent Depression
  • Enuresis
  • Epilepsy
  • Juvenile Rheumatoid Arthritis
  • Other Mental Disorders
• Description of Products
  • Analgesics and Non-Steroidal Anti-inflammatory Drugs
  • Anesthetics
  • Antidepressants
  • Antipsychotics
  • Antiseizure Agents
  • Central Nervous Stimulants
  • Sedatives, Hypnotics, and Anxiolytics
• Miscellaneous Central Nervous System Drugs
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
• Competitive Analysis

Chapter Eight: Prescription Pediatric Gastrointestinal Drugs

• Overview
• Description of Conditions and Diseases
  • Chronic Conditions
  • Acute Conditions
• Prevalence and Incidence
  • Gastroesophageal Reflux (GER)
  • Inflammatory Bowel Disease
  • Peptic Ulcer Disease
  • Irritable Bowel Syndrome
• Description of Products
  • Antidiarrheals
  • Antiemetics/Emetics
  • Histamine H2 Antagonists
  • Miscellaneous Gastrointestinal Drugs (Including PPIs)
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
• Competitive Analysis

Chapter Nine: Prescription Pediatric Hormone Drugs

• Overview
• Description of Conditions and Diseases
  • Hypopituitarism
  • Precocious Puberty
  • Diabetes Insipidus
  • Hypothyroidism
  • Hyperthyroidism
  • Lymphocytic Thyroiditis
  • Diabetes Mellitus
• Prevalence and Incidence
  • Diabetes Insipidus
  • Diabetes Mellitis
  • Hyperthyroidism
  • Hypopitutitarism
  • Hypothyroidism
  • Lymphocytic Thyroiditis
  • Precocious Puberty
• Description of Products
  • Antidiabetic Agents
  • Antidiuretic Hormones
  • Growth Hormone Drugs
  • Steroids/Corticosteroids
  • Thyroid Drugs
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
• Competitive Analysis

Chapter Ten: Other Prescription Pediatric Drugs

• Overview
• Description of Conditions and Diseases
  • Dental
  • Dermatological
  • Ophthalmic
• Prevalence and Incidence
  • Acne
  • Dental Caries
  • Glaucoma
• Description of Products
  • Dental Products
  • Dermatologic Drugs
  • Ophthalmic Drugs
  • Miscellaneous Drugs
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
• Competitive Analysis

Chapter Eleven: Pediatric Research and Development

• Overview

Chapter Twelve: Issues and Trends Affecting the Pediatric Drug Market

Chapter Thirteen: Total Market Size and Forecast

• Overview
• Total market Size and Forecast
• Markets by Segments
• Competitor Analysis
• Market Analysis

Chapter Fourteen: Corporate Profiles

• Introduction
• Leading Corporate Profiles
  • Abbott Laboratories
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly & Company
  • Genentech, Inc.
  • GlaxoSmithKline
  • Johnson & Johnson Group
  • MedImmune, Inc.
  • Merck & Company, Inc.
  • Novartis Pharmaceuticals Corporation
  • Novo Nordisk Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Roche
  • Sanofi-Aventis
  • Schering-Plough Corporation
  • Wyeth
  • Other and Emerging Companies at a Glance
    • Alcon Pharmaceuticals
    • Alkermes, Inc.
    • Allergan
    • Antex Biologics
    • Ascent Pediatrics
    • AstraZeneca plc
    • Celltech Group plc
    • Chiron Corporation
    • Daiichi Pharmaceutical
    • Discovery Laboratories, Inc.
    • Elan Corporation plc
    • Genzyme Corporation
    • Targacept (Layton BioSciences)
    • Mallinckrodt Pharmaceuticals
    • Milkhaus Laboratory, Inc.
    • Muro Pharmaceutical, Inc.
    • Nastech Pharmaceutical Company, Inc.
    • Orphan Medical, Inc.
    • Pharmacyclics, Inc.
    • Sepracor, Inc.
    • Shire Pharmaceuticals Group PLC
    • Triangle Pharmaceuticals, Inc.
    • Valeant Pharmaceuticals
    • Vertex Pharmaceuticals, Inc.

Appendix Company Directory

list of exhibits

Chapter One

• Table 1-1 The World Market for Prescription Pediatric Drugs, 2004-2011
• Figure 1-1 The World Market for Prescription Pediatric Drugs, 2004-2011

Chapter Two

• Table 2-1 Total World and Regional Pediatric Populations by Age Group 2004-2011
• Figure 2-1 World Pediatric Population by Geographic Region 2004, 2006, 2011
• Table 2-2 World Pediatric Population by More and Less Developed Countries (in millions) 2004, 2004, 2009
• Figure 2-2 World Pediatric Population by More and Less Developed Countries 2004, 2006, 2011
• Table 2-3 World Population Distribution by Age Group 2004-2050

Chapter Three

• Table 3-1 World Prevalence, Incidence and Mortality of Selected Pediatric Allergy and Respiratory Conditions
• Figure 3-1 World Prevalence of Selected Pediatric Respiratory Conditions in Comparison to the Total Pediatric Population
• Table 3-2 Selected Prescription Antihistamines and Combinations for Pediatric Administration
• Table 3-3 Selected Prescription Antiasthmatics for Pediatric Administration
• Table 3-4 Selected Prescription Bronchodilators for Pediatric Administration
• Table 3-5 Selected Prescription Corticosteroids for Pediatric Administration
• Table 3-6 Selected Prescription Decongestants and Combinations for Pediatric Administration
• Table 3-7 Selected Prescription Expectorants for Pediatric Administration
• Table 3-8 Selected Prescription Lung Surfactants for Pediatric Administration
• Table 3-9 The World Market for Prescription Pediatric Allergy and Respiratory Drugs, 2004-2011
• Figure 3-2 The World Market for Prescription Pediatric Allergy and Respiratory Drugs, 2004-2011
• Table 3-10 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Product Type (Antihistamines/Combinations, Antiasthmatics, Bronchdilators, Corticosteroids, Decongestants/Combinations, Expectorants/Antitussives/Combinations, Lung Surfectants) 2004-2011
• Figure 3-3 The World Market for Prescription Pediatric Allergy and Respiratory Drugs, by Product Type, 2004-2011
• Figure 3-4 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Product Type and Percent Distribution, 2004-2011
• Figure 3-5 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Percent and Product Type, 2006
• Table 3-11 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Geographic Region (U.S. vs. Non-U.S) 2004, 2006, and 2011
• Figure 3-6 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Geographic Region, 2004, 2006, and 2011
• Table 3-12 Leading Suppliers' Shares of the World Market for Prescription Pediatric Drugs: Allergy and Respiratory Drugs, 2004
• Figure 3-7 Leading Suppliers' Shares of the World Market for Prescription Pediatric Drugs: Allergy and Respiratory Drugs, 2006

Chapter Four

• Table 4-1 Global Prevalence, Incidence and Mortality of Selected Viral and Bacterial Infections
• Figure 4-1 World Incidence of Selected Pediatric Viral and Bacterial Infections in Comparison to Pediatric Population
• Figure 4-2 World Prevalence of Selected Pediatric Viral Infections in Comparison to Total Pediatric Population
• Table 4-2 Selected Prescription Antibiotics for Pediatric Administration
• Table 4-3 Selected Prescription Antifungals for Pediatric Administration
• Table 4-4 Selected Prescription Antiparasitics for Pediatric Administration
• Table 4-5 Selected Prescription Anti-virals for Pediatric Administration
• Table 4-5 Selected Prescription Anti-virals for Pediatric Administration
• Table 4-7 Selected Prescription Miscellaneous Anti-infectives for Pediatric Administration
• Table 4-9 The World Market for Prescription Pediatric Drugs: Anti-infectives, 2004-2011
• Figure 4-3 The World Market for Prescription Pediatric Drugs: Anti-infectives, 2004-2011
• Table 4-8 The World Market for Prescription Pediatric Anti-Infectives by Product Type, 2004-2011
• Figure 4-4 The World Market for Prescription Pediatric Anti-Infectives by Product Type 2004-2011
• Table 4-9 The World Market for Prescription Pediatric Anti-infectives by Geographic Region, 2004, 2006, and 2011
• Figure 4-5 The World Market for Prescription Pediatric Anti-infectives by Geographic Region, 2004, 2006, and 2011
• Table 4-10 Leading Suppliers' Shares of the World Market for Prescription Pediatric Drugs: Anti-Infectives, 2006
• Figure 4-6 Leading Suppliers' Shares of the World Market for Prescription Pediatric Drugs: Anti-Infectives, 2006

Chapter Five

• Table 5-1 World Incidence of Selected Pediatric Cancers
• Figure 5-1 World Incidence of Selected Pediatric Cancers as a Comparison to All Pediatric Cancers
• Table 5-2 Selected Prescription Alkylating Agents for Pediatric Administration
• Table 5-3 Selected Prescription Antimetabolites for Pediatric Administration
• Table 5-4 Selected Prescription Antineoplastic Antibiotics for Pediatric Administration
• Table 5-5 Selected Prescription Mitotic Inhibitors for Pediatric Administration
• Table 5-6 Selected Prescription Miscellaneous Cancer Therapies for Pediatric Administration
• Table 5-7 The World Market for Prescription Pediatric Cancer Therapies, 2004-2011
• Figure 5-2 The World Market for Prescription Pediatric Cancer Therapies, 2004-2011
• Table 5-8 The World Market for Prescription Pediatric Cancer Therapies, by Product Type 2004-2011
• Figure 5-3 The World Market for Prescription Pediatric Cancer Therapies by Product Type, 2004-2011
• Figure 5-5 The World Market for Prescription Pediatric Cancer Therapies, Distribution of Revenues by Product Type 2006
• Table 5-9 The World Market for Prescription Pediatric Cancer Therapies, by Geographic Region, 2004, 2006, and 2011
• Figure 5-6 The World Market for Prescription Pediatric Cancer Therapies by Geographic Region, 2004, 2006, and 2011
• Table 5-10 Leading Suppliers' Shares of the World Market for Prescription PediatricCancer Therapies, 2006
• Figure 5-7 Leading Suppliers' Shares of the World Market for Prescription Pediatric Cancer Therapies, 2006

Chapter Six

• Table 6-1 World Prevalence, Incidence and Mortality of Cardiovascular Conditions in Pediatric Population
• Figure 6-1 World Prevalence of Pediatric Cardiovascular Conditions in Comparison to Pediatric Populations
• Table 6-2 Selected Prescription Anticoagluants for Pediatric Administration
• Table 6-3 Selected Prescription Antidysrhythmics for Pediatric Administration
• Table 6-4 Selected Prescription Antihypertensives for Pediatric Administration
• Table 6-5 Selected Prescription Cardiac Glycosides for Pediatric Administration
• Table 6-6 Selected Prescription Miscellaneous Cardiovascular Drugs for Pediatric Administration
• Table 6-7 The World Market for Prescription Pediatric Drugs: Cardiovascular Drugs, 2004-2011
• Figure 6-2 The World Market for Prescription Pediatric Drugs: Cardiovascular Drugs, 2004-2011
• Table 6-8 The World Market for Prescription Pediatric Cardiovascular Drugs by Product Type (Anticoagulants, Antidysrhythmics, Antihypertensives, Cardiac Glycosides, Misc) 2004-2011
• Figure 6-3 The World Market for Prescription Pediatric Cardiovascular Drugs by Product Type, 2004-2011
• Figure 6-4 The World Market for Prescription Pediatric Cardiovascular Drugs, Revenue Distribution by Product Type, 2006
• Table 6-9 The World Market for Prescription Pediatric Cardiovascular Drugs by Geographic Region, 2004, 2006, and 2011
• Figure 6-5 The World Market for Prescription Pediatric Cardiovascular Drugs by Geographic Region, 2004, 2006, and 2011
• Table 6-10 Leading Suppliers' Shares of the World Market for Prescription Pediatric Cardiovascular Drugs, 2006
• Figure 6-10 Leading Suppliers' Shares of the World Market for Prescription Pediatric Cardiovascular Drugs, 2006

Chapter Seven

• Table 7-1 World Prevalence of Selected Pediatric Central Nervous System Conditions
• Figure 7-1 World Prevalence of Selected Pediatric Central Nervous System Conditions in Comparison to Pediatric Population
• Table 7-2 Selected Prescription Analgesic and Non-steroidal Anti-inflammatory Drugs for Pediatric Administration
• Table 7-3 Selected Prescription Anesthetics for Pediatric Administration
• Table 7-4 Selected Prescription Antidepressants for Pediatric Administration
• Table 7-5 Selected Prescription Antipsychotic Drugs for Pediatric Administration
• Table 7-6 Selected Prescription Antiseizure Agents for Pediatric Administration
• Table 7-7 Selected Prescription Central Nervous Stimulants for Pediatric Administration
• Table 7-8 Selected Prescription Sedatives, Hypnotics, and Anxiolytics for Pediatric Administration
• Table 7-9 Selected Prescription Miscellaneous Central Nervous System Agents for Pediatric Administration
• Table 7-10 The World Market for Prescription Pediatric Central Nervous System Drugs, 2002-2011
• Figure 7-2 The World Market for Prescription Pediatric Central Nervous System Drugs, 2002-2011
• Table 7-11 The World Market for Prescription Pediatric Central Nervous System Drugs by Product Type (Analgesics/NSAIDs, Anesthetics, Anti-depressants/Antipsychotics, Antiseizure Agents, CNS Stimulants, Sedatives/Hypnotics/Anxiolytics, and Miscellaneous ), 2004-2011
• Figure 7-3 The World Market for Prescription Pediatric Central Nervous System Drugs by Product Type, 2004-2011
• Figure 7-4 The World Market for Prescription Pediatric Central Nervous System Drugs, Revenue Distribution by Product Type, 2006
• Table 7-12 The World Market for Prescription Pediatric Central Nervous System Drugs by Geographic Region 2004, 2006, and 2011
• Figure 7-5 The World Market for Prescription Pediatric Central Nervous System Drugs by Geographic Region, 2004, 2006, and 2011
• Table 7-13 Leading Suppliers' Shares of the World Market for Prescription Pediatric Central Nervous System Drugs, 2006
• Figure 7-6 Leading Suppliers' Shares of the World Market for Prescription Pediatric Drugs: Central Nervous System Drugs, 2006

Chapter Eight

• Table 8-1 Global Prevalence, Incidence, and Mortality of Gastrointestinal Conditions in Pediatric Populations
• Figure 8-1 World Incidence of Pediatric Gastrointestinal Conditions in Comparison to Pediatric Population
• Figure 8-2 World Prevalence of Pediatric Gastrointestinal Conditions Compared to Pediatric Populations
• Table 8-2 Selected Prescription Antidiarrheals for Pediatric Administration
• Table 8-3 Selected Prescription Antiemetics/Emetics Drugs for Pediatric Administration
• Table 8-4 Selected Prescription Histamine H2 Antagonists for Pediatric Administration
• Table 8-5 Selected Prescription Miscellaneous Gastrointestinal Drugs for Pediatric Administration
• Table 8-6 The World Market for Prescription Pediatric Gastrointestinal Drugs 2004-2011
• Figure 8-3 The World Market for Prescription Pediatric Gastrointestinal Drugs 2004-2011
• Table 8-7 The World Market for Prescription Pediatric Gastrointestinal Drugs by Product Type (Antidiarrheals, Antiemetics/Emetics, H2 Antagonists, Misc Drugs incl PPIs) 2004-2011
• Figure 8-4 The World Market for Prescription Pediatric Gastrointestinal Drugs by Product Type, 2004-2011
• Figure 8-5 The World Market for Prescription Pediatric Gastrointestinal Drugs, Revenue Distribution by Product Type, 2006
• Table 8-7 The World Market for Prescription Pediatric Gastrointestinal Drugs by Geographic Region, 2004, 2006, and 2011
• Figure 8-6 The World Market for Prescription Pediatric Gastrointestinal Drugs by Geographic Region, 2004, 2006, and 2011
• Table 8-8 Leading Suppliers' Shares of the World Market for Prescription Pediatric Gastrointestinal Drugs, 2006
• Figure 8-11 Leading Suppliers' Shares of the World Market for Prescription Pediatric Gastrointestinal Drugs, 2006

Chapter Nine

• Table 9-1 World Incidence and Prevalence of Selected Pediatric Hormone Conditions
• Figure 9-1 World Incidence of Selected Pediatric Hormone Conditions in Comparison to Pediatric Population
• Figure 9-2 World Prevalence of Selected Pediatric Hormone Conditions in Comparison to Pediatric Population
• Table 9-2 Selected Prescription Antidiabetic Agents for Pediatric Administration
• Table 9-3 Selected Prescription Antidiuretic Hormones for Pediatric Administration
• Table 9-4 Selected Prescription Growth Hormone Drugs for Pediatric Administration
• Table 9-5 Selected Prescription Steroids/Corticosteroids for Pediatric Administration
• Table 9-6 Selected Prescription Thyroid Drugs for Pediatric Administration
• Table 9-7 The World Market for Prescription Pediatric Hormone Drugs, 2004-2011
• Figure 9-2 The World Market for Prescription Pediatric Hormone Drugs, 2004-2011
• Table 9-8 The World Market for Prescription Pediatric Hormone Drugs by Product Type, 2004-2011
• Figure 9-3 The World Market for Prescription Pediatric Hormone Drugs by Product Type, 2004-2011
• Figure 9-4 The World Market for Prescription Pediatric Hormone Drugs, Revenue Distribution by Product Type, 2006
• Table 9-9 The World Market for Prescription Pediatric Hormone Drugs by Geographic Region, 2004, 2006, and 2011
• Figure 9-7 The World Market for Prescription Pediatric Drugs: Hormone Drugs, by Geographic Region, 2004, 2006, and 2011
• Table 9-10 Leading Suppliers' Shares of the World Market for Prescription Pediatric Drugs: Hormone Drugs, 2006
• Figure 9-11 Leading Suppliers' Shares of the World Market for Prescription Pediatric Drugs: Hormone Drugs, 2006

Chapter Ten

• Table 10-1 World Incidence of Other Pediatric Conditions
• Figure 10-2 World Incidence/Prevalence of Other Pediatric Conditions in Comparison to Pediatric Populations
• Table 10-2 Selected Prescription Dental Products for Pediatric Administration
• Table 10-3 Selected Prescription Dermatologic Drugs for Pediatric Administration
• Table 10-4 Selected Prescription Ophthalmic Drugs for Pediatric Administration
• Table 10-5 Selected Prescription Miscellaneous Drugs for Pediatric Administration
• Table 10-6 The World Market for Miscellaneous Pediatric Prescription Drugs 2004-2011
• Figure 10-2 The World Market for Miscellaneous Pediatric Prescription Drugs, 2004-2011
• Table 10-7 The World Market for Miscellaneous Pediatric Prescription Drugs by Product Type, 2004-2011
• Figure 10-3 The World Market for Miscellaneous Pediatric Prescription Drugs by Product Type, 2004-2011
• Figure 10-4 The World Market for Miscellaneous Pediatric Prescription Drugs, Revenue Distribution by Product Type 2006
• Table 10-8 The World Market for Miscellaneous Pediatric Prescription Drugs, by Geographic Region, 2004, 2006, and 2011
• Figure 10-5 The World Market for Miscellaneous Pediatric Prescription Drugs, by Geographic Region, 2004, 2006, and 2011

Chapter Eleven

• Table 11-1 Products Recently Approved or in Various Stages of Development for Pediatrics
• Table 11-2 Approved Prescription Drugs for which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population
• Table 11-3 Approved Prescription Biologics for which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population

Chapter Twelve

• Table 12-1 Label Changes for Pediatric Drugs
• Table 12-2 FDA Approved Drugs with Pediatric Exclusivity and Patent Expiration Date
• Table 12-3 Requests Issued and Received for Pediatric Exclusivity by FDA Review Division as of September, 2005

Chapter Thirteen

• Table 13-1 The World Market for Prescription Pediatric Drugs, 2004-2011
• Figure 13-1 The World Market for Prescription Pediatric Drugs, 2004-2011
• Table 13-2 The World Market for Prescription Pediatric Drugs by Therapeutic Area, 2004-2011
• Figure 13-2 The World Market for Prescription Pediatric Drugs by Therapeutic Area, 2004-2011
• Figure 13-4 The World Market for Prescription Pediatric Drugs, Revenue Distribution by Therapeutic Area, 2006
• Table 13-5 Leading Suppliers Segments of Participation in the World Market for Prescription Pediatric Drugs, 2006

Chapter Fourteen

Appendix